| Non Small Cell Lung Cancer | | Zeeshan
(702) 822-5200 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC) |
| Non Small Cell Lung Cancer | | Zeeshan
(702) 822-5200 | Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Non Small Cell Lung Cancer | | Christine
(702) 822-5456 | CBP501, pemetrexed and cisplatin as first line treatment in patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous non small cell lung cancer (NSCLC) |
| Non Small Cell Lung Cancer | | Christine
(702) 822-5456 | STA-9090 in Subjects with Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) |
| Non Small Cell Lung Cancer | | Christine
(702) 822-5456 | ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (Stage IIIb/IV) non-small cell lung cancer (NSCLC) |
| Non Small Cell Lung Cancer | | Shamine
(702) 822-5142 | Genetic Epidemiology of Lung Cancer I (GELCC) |
| Non Small Cell Lung Cancer | | Shamine
(702) 822-5142 | Genetic Epidemiology of Lung Cancer I (GELCC) |
| Mesothelioma | | Christine
(702) 822-5456 | CBP501, pemetrexed and cisplatin in patients with advanced solid tumors and in chemotherapy-naïve patients with malignant pleural mesothelioma |